The assumption that improved tumor exposure might lead to greater efficacy of AZD8701 is supported by the immunological effects observed in the periphery, specifically the increased levels of Ki67+ CD8 T cells in the blood (Fig. 4D), which indicate T-cell activation. Here, MKI67 is linked to neoplasm.